
Danish biotech company Bavarian Nordic can once again announce positive results from a phase II study of its corona vaccine, ANBCoV2. The results from two remaining patient groups have now been analyzed and found to support the vaccine’s ability to boost neutralizing antibodies to levels that protect the individual against Covid-19.
Bavarian has previously reported of a strong boosting effect from its vaccine in a 100 mcg dose in people who had already received vaccine shots.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app